Becton, Dickinson and Company (NYSE:BDX) Stake Lowered by Koshinski Asset Management Inc.

Koshinski Asset Management Inc. trimmed its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.6% in the 3rd quarter, Holdings Channel.com reports. The fund owned 5,973 shares of the medical instruments supplier’s stock after selling 96 shares during the quarter. Koshinski Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $1,440,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Livelsberger Financial Advisory purchased a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth about $27,000. Scarborough Advisors LLC acquired a new stake in Becton, Dickinson and Company in the fourth quarter valued at approximately $32,000. Rise Advisors LLC bought a new stake in Becton, Dickinson and Company in the first quarter worth approximately $38,000. Opal Wealth Advisors LLC acquired a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth $45,000. Finally, Abound Wealth Management increased its stake in shares of Becton, Dickinson and Company by 96.0% during the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 96 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BDX. Stifel Nicolaus upped their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Raymond James decreased their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Evercore ISI upped their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $236.50 on Monday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $262.55. The company has a fifty day moving average price of $236.37 and a 200 day moving average price of $235.30. The stock has a market cap of $68.35 billion, a P/E ratio of 52.09, a PEG ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. During the same quarter in the prior year, the business earned $2.96 earnings per share. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. Analysts anticipate that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 1.61%. The ex-dividend date of this dividend was Monday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 83.70%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.